Respiri Limited signs joint development agreement with Phenix Health, surges 50%
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management, hit a high of 11.5 cents on Tuesday, representing a 55% rise relative to its previous closing price of 7.4 cents.
The sharp uptick in the company’s share price was under the highest volumes traded in 2020, underlining the significance of the news released shortly after the market opened.
The signing of a Joint Development Agreement (JDA) with Phenix Health Pty Ltd, an Australian based health workflow designer for virtual healthcare settings (telemedicine) triggered substantial investor interest.
Under the terms of the JDA, Respiri will work to ensure that the wheezo eHealth SaaS monitoring platform is integrated into the Phenix proprietary telehealth platform, patient dashboards and asthma management plans.
Respiri’s world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation.
The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.
Phenix to provide pre-diagnosed patients
Phenix will we be responsible for providing patients already diagnosed with asthma the option of using wheezo to help monitor their condition, providing healthcare beyond the clinic setting.
Mr Marjan Mikel, managing director of Respiri said, “The joint development agreement with Phenix underscores our commitment to patients with asthma and related respiratory disease in Australia during the COVID-19 pandemic.
‘’By increasing awareness and access through Phenix’s leading telehealth platform, innovative technology solutions such as wheezo will support more effective monitoring of a patient’s underlying condition to better empower patients and their treating physicians in the management of their condition during this critical period and beyond.”
Ms Gillian Alexis, Chief Executive of Phenix Health commented that the group was keen to pursue other initiatives with Respiri in saying, “This ground-breaking partnership represents an improvement in quality of life for the world’s 340 million asthma sufferers and will provide primary care providers as well as respiratory specialists with new key insights to help patients manage their asthma proactively.
‘’We look forward to evolving new longitudinal models of care with Respiri that are focused on measurable outcomes by complementing traditional brick and mortar services.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
